
Waters (WAT) Stock Forecast & Price Target
Waters (WAT) Analyst Ratings
Bulls say
Waters is in a strong position to drive growth and margin expansion through its recent acquisition of Becton Dickinson's life science and diagnostics businesses, which adds a significant earnings-growth driver and cost-saving opportunities. Waters' leadership in liquid chromatography, mass spectrometry, and thermal analysis tools, combined with its exposure to drug manufacturing, makes it well-positioned for sustained growth as drug production ramps up in the US and abroad. The company also has potential for further industry consolidation, bolstered by its strong cash flow and track record for successful acquisitions.
Bears say
Waters is currently undergoing a management change and has recently merged with Becton Dickinson's life science and diagnostics business, which may raise execution risks and make it challenging for them to turn around the underperforming assets. Additionally, while demand is expected to recover, competition and market saturation may limit Waters' ability to fully capitalize on a major analytical-instrument replacement cycle. The company also faces sustainability concerns and a constrained balance sheet, which may limit their capital allocation flexibility. Therefore, the negative outlook remains.
This aggregate rating is based on analysts' research of Waters and is not a guaranteed prediction by Public.com or investment advice.
Waters (WAT) Analyst Forecast & Price Prediction
Start investing in Waters (WAT)
Order type
Buy in
Order amount
Est. shares
0 shares